SGHT (SGHT) revenue breakdown
By segment, Interventional Glaucoma is the largest at 98% of fiscal 2025 revenue, growing 24% a year over 5 years.
Revenue by segment
Fiscal years, as SGHT reports them in its 10-K filings; fiscal 2025 total $77M.
| Segments | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Interventional Glaucoma | $26M | $46M | $66M | $74M | $76M | $76M | 98% |
| Interventional Dry Eye | $2M | $2M | $6M | $7M | $4M | $2M | 2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SGHT.
Open SGHT in InvestinglyQuestions
Where does SGHT make its money?
In fiscal 2025, by segment: Interventional Glaucoma $76M, Interventional Dry Eye $2M.
From SGHT's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.